Correction: Panjideh et al. Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861. Toxins 2022, 14, 478

Panjideh, Hossein; Niesler, Nicole; Weng, Alexander; Fuchs, Hendrik

doi:10.3390/toxins14100703

Cited by 3 publications

(4 citation statements)

References 2 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five human 5-HT 3 receptor subunits have been cloned and homo-oligomeric assemblies of 5-HT 3 A and hetero-oligomeric assemblies of 5-HT 3 A and 5-HT 3 B subunits have been characterised in detail. The 5-HT 3 C (HTR3C, Q8WXA8), 5-HT 3 D (HTR3D, Q70Z44) and 5-HT 3 E (HTR3E, A5X5Y0) subunits [506,764], like the 5-HT 3 B subunit, do not form functional homomers, but are reported to assemble with the 5-HT 3 A subunit to influence its functional expression rather than pharmacological profile [419,766,1115]. 5-HT 3 A, -C, -D, and -E subunits also interact with the chaperone RIC-3 which predominantly enhances the surface expression of homomeric 5-HT 3 A receptor [1115].…”

Section: -Ht 3 Receptorsmentioning

confidence: 99%

“…However, 5-HT 3 A and 5-HT 3 AB receptors differ in their allosteric regulation by some general anaesthetic agents, small alcohols and indoles [433,916,990]. The potential diversity of 5-HT 3 receptors is increased by alternative splicing of the genes HTR3A and E [115,424,763,765,766]. In addition, the use of tissue-specific promoters driving expression from different transcriptional start sites has been reported for the HTR3A, HTR3B, HTR3D and HTR3E genes, which could result in 5-HT 3 subunits harbouring different N-termini [470,763,1076].…”

Section: -Ht 3 Receptorsmentioning

confidence: 99%

See 1 more Smart Citation

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels

Alexander

Mathie

Peters

et al. 2021

British J Pharmacology

200

167

View full text Add to dashboard Cite

The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.15539. Ion channels are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2021, and supersedes data presented in the 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

show abstract

Section: -Ht 3 Receptorsmentioning

confidence: 99%

Section: -Ht 3 Receptorsmentioning

confidence: 99%

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels

Alexander

Mathie

Peters

et al. 2021

British J Pharmacology

200

167

View full text Add to dashboard Cite

show abstract

“…Five human 5-HT 3 receptor subunits have been cloned and homo-oligomeric assemblies of 5-HT 3 A and hetero-oligomeric assemblies of 5-HT 3 A and 5-HT 3 B subunits have been characterised in detail. The 5-HT 3 C (HTR3C, Q8WXA8), 5-HT 3 D (HTR3D, Q70Z44) and 5-HT 3 E (HTR3E, A5X5Y0) subunits [574,873], like the 5-HT 3 B subunit, do not form functional homomers, but are reported to assemble with the 5-HT 3 A subunit to influence its functional expression rather than pharmacological profile [475,875,1276]. 5-HT 3 A, -C, -D, and -E subunits also interact with the chaperone RIC-3 which predominantly enhances the surface expression of homomeric 5-HT 3 A receptor [1276].…”

Section: -Ht 3 Receptorsmentioning

confidence: 99%

“…However, 5-HT 3 A and 5-HT 3 AB receptors differ in their allosteric regulation by some general anaesthetic agents, small alcohols and indoles [490,1046,1133]. The potential diversity of 5-HT 3 receptors is increased by alternative splicing of the genes HTR3A and HTR3E [136,480,872,874,875]. In addition, the use of tissue-specific promoters driving expression from different transcriptional start sites has been reported for the HTR3A, HTR3B, HTR3D and HTR3E genes, which could result in 5-HT 3 subunits harbouring different N-termini [531,872,1231].…”

Section: -Ht 3 Receptorsmentioning

confidence: 99%

The Concise Guide to PHARMACOLOGY 2023/24: Ion channels

Alexander,

Mathie,

Peters

et al. 2023

British J Pharmacology

View full text Add to dashboard Cite

The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and over 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org/), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.16178. Ion channels are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

show abstract